Description
Aromatase excess syndrome is a condition characterized by elevated levels of the female sex hormone estrogen in both males and females. Males with aromatase excess syndrome experience breast enlargement (gynecomastia) in late childhood or adolescence. The bones of affected males grow and develop more quickly and stop growing sooner than usual (advanced bone age). As a result males have an early growth spurt, typically during late childhood, with short stature as an adult. Affected females rarely show signs and symptoms of the condition, but they may have increased breast growth (macromastia), irregular menstrual periods, and short stature. The ability to have children (fertility) is usually normal in both males and females with aromatase excess syndrome.
Causes
Rearrangements of genetic material involving the CYP19A1 gene cause aromatase excess syndrome. The CYP19A1 gene provides instructions for making an enzyme called aromatase. This enzyme converts a class of hormones called androgens, which are involved in male sexual development, to different forms of estrogen. In females, estrogen guides female sexual development before birth and during puberty. In both males and females, estrogen plays a role in regulating bone growth.
The condition can result from several types of genetic rearrangements involving the CYP19A1 gene. These rearrangements alter the activity of the gene and lead to an increase in aromatase production. In affected males, the increased aromatase and subsequent conversion of androgens to estrogen are responsible for the gynecomastia and limited bone growth characteristic of aromatase excess syndrome. Increased estrogen in females can cause symptoms such as irregular menstrual periods and short stature.
Key Clinical Features
In Males: The most distinct sign is bilateral breast enlargement (gynecomastia) that appears in late childhood or adolescence and persists for life. Affected boys also experience an early growth spurt, advanced bone age, and early fusion of the growth plates, which ultimately causes short stature as an adult. They may also experience mild testosterone deficiency.
In Females: Females usually show few, if any, outward signs of the condition. However, some may experience increased breast growth (macromastia), irregular periods, and short adult stature.
Fertility: Despite hormone imbalances, fertility is generally unimpaired in both sexes
The condition is inherited in an autosomal dominant pattern. It results from genetic rearrangements (such as duplications, deletions, or inversions) near the CYP19A1 gene. These rearrangements cause the aromatase enzyme—which converts androgens into estrogens—to be overactive or expressed in tissues where it shouldn't be
Diagnosis
Diagnosis relies on:
- Hormone Testing: Elevated levels of circulating estrogens (estradiol and estrone).
- Bone Age Assessment: X-rays showing accelerated bone maturation.
- Genetic Testing: Molecular analysis verifying structural abnormalities in the CYP19A1 gene
Management
Management often requires a multidisciplinary approach involving pediatric endocrinologists and may include:
Aromatase Inhibitors: Medications such as anastrozole or letrozole are frequently prescribed to block the excess conversion of androgens into estrogens, thereby reducing gynecomastia and preventing premature bone closure.
Surgery: Cosmetic or reconstructive mastectomy is sometimes performed to remove excess breast tissue, especially to alleviate psychological distress
Comments
Post a Comment